What is one of the results of using AChE inhibitors in Alzheimer's therapy?

Using acetylcholinesterase (AChE) inhibitors in the treatment of Alzheimer's disease leads primarily to increased levels of acetylcholine in the brain. This class of drugs works by blocking the enzyme acetylcholinesterase, which is responsible for breaking down acetylcholine, a neurotransmitter critical for learning and memory. In Alzheimer's patients, there is a significant decrease in acetylcholine due to the neurodegenerative processes associated with the disease. By inhibiting the action of acetylcholinesterase, these medications prolong the presence and availability of acetylcholine, thereby enhancing cholinergic neurotransmission.

This increased availability of acetylcholine can lead to improved cognitive functions and may help alleviate some symptoms of Alzheimer's disease, providing symptomatic relief. This mechanism is important in the overall strategy for managing cognitive decline in affected individuals.

The other choices do not reflect the pharmacological effects of AChE inhibitors. Enhanced muscle strength, decreased appetite, and improved visual acuity are not direct outcomes related to the mechanism of AChE inhibitors. These choices either pertain to different physiological functions unrelated to the cholinergic system or are not typically observed effects of AChE inhibitor therapy in the context of Alzheimer's treatment.